Silver Touch Technologies reported a strong Q1 FY27 performance, with net profit rising 148% YoY to Rs 10.01 crore. The company is successfully shifting from hardware reselling to high-margin proprietary software, leading to an 88% jump in EBITDA. Key government project wins, including work for the Indian Navy and AIIMS, coupled with the launch of its Ai4Pharma subsidiary, signal a strategic pivot toward recurring revenue. Margin expansion highlights improved operating leverage, though investors should keep an eye on government project timelines and international execution risks.
Silver Touch Technologies Q1 FY27 Profit Jumps 148%
Revenue at Rs 76.72 crore; PAT at Rs 10.01 crore
Reader Takeaway: Margin expansion driven by a shift to software services balances the risk of government project concentration.
What just happened
Silver Touch Technologies posted a stellar Q1 FY27, with net profit (PAT) reaching Rs 10.01 crore, a 147.7% increase compared to Rs 4.04 crore in the same quarter last year. Revenue from operations grew 22.26% to Rs 76.72 crore. The company successfully executed a pivot away from hardware reselling, evidenced by a significant 76% drop in stock-in-trade expenses.
Why this matters
The company is transitioning toward a proprietary software-led model, which is far more scalable than its legacy hardware business. This shift is clearly visible in the EBITDA margins, which expanded by 782 bps to 22.22%. By securing high-value mandates from marquee institutions like the Indian Navy, the Ministry of External Affairs, and AIIMS New Delhi, the company is building a strong foundation of predictable, long-duration revenue.
What changes now
Silver Touch has incorporated a new subsidiary, Ai4Pharma, specifically targeting the global pharmaceutical market. This arm aims to capture recurring revenue from global manufacturing plants using products like ChatGMP and LabelSmart. This diversification into high-compliance global markets is a strategic attempt to move beyond domestic government project reliance.
Risks to watch
Despite the growth, the business remains heavily weighted toward government and public sector institutions. Any delay in project approvals or tender releases could impact top-line growth. Additionally, scaling the Ai4Pharma suite globally introduces new execution and regulatory hurdles that will require consistent management attention to maintain the current high margins.
What to track next
Investors should look for the commercial rollout progress of the Ai4Pharma suite. Monitoring the ability of the management to secure similar recurring revenue contracts in the private sector will be vital to de-risking the current reliance on public-sector mandates.